Search of: msh2 - List Results - ClinicalTrials.gov

Found 4 studies with search of:

msh2

.

1	Recruiting	Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency Condition: Advanced Colorectal Cancer Intervention: Drug: Methotrexate
2	Recruiting	Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom Condition: Endometrial Cancer Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
3	Recruiting	Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom Condition: Colorectal Cancer Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
4	Recruiting	Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Lung Cancer; Melanoma; Non-Hodgkin's Lymphoma; Uterine Cancer; CORPUS UTERI,ENDOMETRIUM; Lung; Ovary Intervention:

carcinoma vs adenocarcinoma - definitions

Definitions of carcinoma on the Web: 

• any malignant tumor derived from epithelial tissue; one of the four major types of cancer
  wordnetweb.princeton.edu/perl/webwn
• A carcinoma is any cancer that arises from epithelial cells. Carcinomas invade surrounding tissues and organs and may metastasize, or spread, to lymph nodes and other sites.
  en.wikipedia.org/wiki/Carcinoma
  pathology2.jhu.edu/PANCREAS/agloss.cfm
• A malignancy arising from a tissue that lines a body cavity. Skin, gut, breasts, prostate are epithelial lining cell cancers and constitute the most common form of cancers in the human body.
  www.sharedexperience.org/Glossary.lasso
  
• A subtype of cancer that develops from tissues covering or lining organs or glands of the body, such as skin, colon, lung, or breast. Most of the cancers are carcinomas. Some cancers that arise from connective tissues like bone are called sarcomas. ...
  medicineworld.org/cancer/descriptions.html
• A malignant tumor that begins in the lining layer (epithelial cells) of organs. At least 80% of all cancers are carcinomas.
  www.americanbrachytherapy.org/aboutBrachytherapy/glossary.cfm
• This term refers to cancer of cells that line various organs. This category is the largest and the most common type of cancer.
  www.oncothyreon.com/about/glossary.html 
•  
•  
•  
• 
  
  Definitions of adenocarcinoma on the Web:
  
• malignant tumor originating in glandular epithelium
  wordnetweb.princeton.edu/perl/webwn
  
• Any of several forms of carcinoma that originate in glandular tissue
  en.wiktionary.org/wiki/adenocarcinoma
• The form of cancer that most people are talking about when they refer to "cancer of the pancreas." These tumors account for 75% of all pancreas cancers. Microscopically, adenocarcinomas form glands. These tumors can grow large enough to invade nerves which can cause back pain. ...
  pathology2.jhu.edu/PANCREAS/agloss.cfm
• Cancerous cell growth in a glandular or glandlike pattern. This cancer can occur in various organs and is the most common cancer of the pancreas (also referred to as adenocarcinoma of the pancreas).
  www.gemzar.com/pat/pat930_glossary.jsp

CBC.ca News - Charities paid $762M to private fundraisers

Note: also see blog "BSB4uD", this article focuses on external fundraisers but the focus should be fundraising costs irrespective of source

"If a charity's not going to be transparent with you on how it's spent money in the past, why would you give it a donation?" she asked.

Money paid by charities spending more than 50% of their revenues on external fundraisers, by province, in 2008:

Province	# of charities	Amount raised ($)	Amount paid to fundraisers ($)	Net revenue for charity ($)
B.C.	38	4,976,236	3,436,926	1,539,310
Alta.	27	19,529,677	16,434,884	3,094,793
Sask.	4	537,703	384,954	152,749
Man.	3	561,674	307,378	254,296
Ont.	100	38,223,556	25,024,532	13,199,024
Que.	28	8,477,161	7,113,096	1,364,065
N.B.	5	750,874	588,702	162,172
N.S.	2	406,617	322,806	83,811
N.L.	3	118,969	88,337	30,632
P.E.I.	4	346,448	264,157	82,291

NIH Office of Rare Diseases Research (ORDR) - Undiagnosed Diseases Program

NIH Office of Rare Diseases Research (ORDR) - Undiagnosed Diseases Program

full free access: Investigating Better Endpoints for Immunotherapy Trials — J. Natl. Cancer Inst.

full free access: PLoS Medicine: Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up? Cochrane Collaboration

"To meet the needs of patients, clinicians, and policymakers, unnecessary trials need to be reduced, and systematic reviews need to be prioritised. Streamlining and innovation in methods of systematic reviewing are necessary to enable valid answers to be found for most patient questions. Finally, clinicians and patients require open access to these important resources."

Women with Cancer: Talking Teal with Cancer Advocate Rebecca Esparza

Note: Rebecca can also be found on FB

Gynecologic Cancer - the Netherlands - Starz Foundation - samen sterk in de strijd tegen gynaecologische kanker

abstract: Resident Participation Does Not Affect Surgical Outcomes, Despite Introduction of New Techniques

Abstract

BACKGROUND: Surgical operations at academic medical centers typically involve a resident physician performing cases together with, and/or under the supervision of, an attending physician. Although this is a widely accepted practice, recent emphasis on patient safety has led to scrutiny about this educational model. There are few studies evaluating whether complication rates, independent of patient risk factors, are affected by resident participation in operations.
STUDY DESIGN: We identified 295 patients (590 breasts) who had undergone bilateral reduction mammoplasty led by a single attending surgeon between October 1, 1997 and September 30, 2008 at the University of Michigan Health System. In all cases, the attending operated on the right breast and the resident operated on the left breast under the supervision of the attending, allowing each patient to act as their own control. Their charts were retrospectively reviewed and major complications were defined as those requiring either an operation or hospitalization to treat.
RESULTS: Twenty-three patients (7.8%) had a major complication after their breast reduction. Ten of these complications occurred in the left breast, 9 in the right breast, and 4 in both breasts. Statistical analysis revealed no differences in major complication rates between the side operated on with the primary surgeon being the resident versus the attending (4.7% versus 4.4%; p = 1.00).
CONCLUSIONS: In the context of this single surgical operation, resident participation does not substantially affect major complication rates. The common residency training paradigm provides clinical experience and supervision without necessarily impacting patient safety. Analysis of additional operations in different settings will be necessary.

ICR (UK) - Lynch Syndrome mutation MSH2 - 60-Year-Old Drug Shows New Promise for Inherited Cancer

"....Methotrexate is similar to a normal molecule called folinic acid, which is required for copying DNA. The drug prevents cells from making and repairing DNA - a process needed for cancer growth. It was one of the first chemotherapy drugs to be invented in the 1940s and is still used to treat a number of cancers today. But until now, it has not commonly been used to treat people with HNPCC.

Professor Alan Ashworth, who led this Cancer Research UK-funded study at the ICR, said: "The MSH2 gene plays a vital role in repairing DNA damage but if it is faulty, mistakes accumulate in cells and increase the risk of cancer developing.

"What's exciting about methotrexate is that it selectively destroys the cells lacking the MSH2 function. This indicates that it may make an excellent treatment for patients with the genetic alteration. With our colleagues at The Royal Marsden Hospital, we have set up clinical trials to test this."...cont'd

A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results

"...Unclassified-variants were most frequently misinterpreted by probands and relatives, and had the largest differences between probands' and relatives' perceptions...."

What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy (abstract)

"This study illustrates that while health care providers are discussing selected side effects of PBSO, women undergoing this surgery have other concerns that should be addressed..."

Microbubble-enhanced US in Body Imaging: What Role? (abstract)

Note: CE US = contrast enhanced ultrasound

Abstract
Contrast agents for ultrasonography (US) comprise microscopic bubbles of gas in an encapsulating shell. They are unique in that they interact with the imaging process, oscillating in response to a low-intensity ultrasound field and disrupting in response to a high-intensity field. New contrast-specific imaging modes allow US to show exquisite vascularity and tissue perfusion in real time and with excellent spatial resolution. In Europe, Asia, and Canada, to name only the most obvious, characterization of focal liver masses is the first and best established use of contrast-enhanced (CE) US, allowing for the noninvasive diagnosis of commonly encountered liver masses with comparable accuracy to that of computed tomography and magnetic resonance studies. CE US is a preferred modality for the difficult task of diagnosis of liver nodules detected on surveillance scans in those at risk for hepatocellular carcinoma. Newer body applications include the guidance of ablative intervention, monitoring activity of bowel inflammation in Crohn disease, characterization of kidney masses, especially cystic renal cell carcinoma, diagnosis of prostate cancer, and monitoring the response of tumors to antivascular drug therapies. Microbubble contrast agents are easy to use and robust; their use poses no risk of nephrotoxicity and requires no ionizing radiation. CE US plays a vital and expanding role that improves management and patient care.

Home : Nature Genetics re: BRCA 1/breast cancer/ polymorphisms (SNP's - international genome study)

Latest highlights

Advance Online Publication

Genetics of breast cancer

Letter by Antonius Antoniou et al.

Fergus Couch and colleagues report a genome-wide association study for modifiers of breast cancer susceptibility in BRCA1 mutation carriers with breast cancer and BRCA1 mutation carriers without breast cancer. They identify a locus at 19p13 associated with breast cancer risk in BRCA1 mutation carriers, and replication studies show that this locus associates with estrogen receptor-negative breast cancer in the general population.

Advance Online Publication

Genetics of ovarian cancer

Letter by Ellen Goode et al. Letter by Kelly Bolton et al.

Simon Gayther and colleagues report a genome wide association study for ovarian cancer. They identify two new susceptibility loci at 2q31 and 8q24. Separately, Paul Pharoah and colleagues report a genome-wide association study for survival time after diagnosis of epithelial ovarian cancer. They identify a locus at 19p13 associated with susceptibility to the serous subtype of epithelial ovarian cancer.

health media: BRCA1 Breast Cancer Risk Linked To Other Genes

"...People who carry certain mutations of the BRCA1 gene are known to have a higher risk of developing breast cancer.

Couch told the media that their findings should be "useful in helping determine individual risk for breast cancer in BRCA1 carriers".

"It also provides insights into hormone-receptor-negative breast cancer in the general population," he added.

For the study, Couch and colleagues conducted four phases of genome-wide association studies (GWAS) that altogether involved 20 research centers in 10 North American and European countries and Israel.

For the first phase, to identify candidate gene variants, they scanned the genomes of 1,193 carriers of BRCA1 mutations who were under 40 and had invasive breast cancer and compared them to scans of about the same number of controls: BRCA1 carriers of similar age who did not have breast cancer.

In comparing the genomes from the two populations the researchers examined over half a million genetic alterations. They found 96 pieces of DNA called SNPs, or "snips", short for single nucleotide polymorphisms, that they thought would be likely candidates because they differed between the two populations...."cont'd

full free access: eMJA: Pathways to the diagnosis of epithelial ovarian cancer in Australia

Note: excerpts below,  the tables included in the paper provide interesting information including patients with borderline tumours, 24% of patients in this study had a prior hysterectomy  etc...

Objective:

To describe the diagnostic pathways experienced by a large, representative group of Australian women with ovarian cancer, and to document the time between first presentation to a medical professional and clinical diagnosis.

Main outcome measures:

Number and type of doctors consulted, investigations performed, referral patterns and the time from first presentation to diagnosis.

Conclusions:

Despite anecdotal suggestions to the contrary, most women with ovarian cancer in Australia are investigated and diagnosed promptly. The diagnostic process is more protracted for a minority of women, and the factors we found to be associated with diagnostic delay warrant further investigation.

"........The numbers of symptoms reported, doctors seen and total doctor visits were all highly skewed. These variables were therefore summarised....."

Maven Semantic: Ovarian Cancer Research Database - media

Note: see website/link for details by individual name and/or country etc

DUBLIN--(BUSINESS WIRE)--Maven Semantic (http://www.mavensemantic.com) announces updates to their Ovarian Cancer research database.
The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.
The database currently tags 42,000 individuals working in Ovarian Cancer. http://bit.ly/d0aEsH

EvidenceUpdates- A randomized controlled trial of home-based exercise for cancer-related fatigue in women during and after chemotherapy with or without radiation therapy

CONCLUSIONS: Our home-based exercise intervention had no effect on fatigue or related symptoms associated with cancer treatment. The optimal timing of exercise remains to be determined.
IMPLICATIONS FOR PRACTICE: Clinicians need to be aware that some physical activity is better than none, and there is no harm in exercise as tolerated during cancer treatment. Further analysis is needed to examine the adherence to exercise. More frequent assessments of fatigue, sleep disturbance, depression, and pain may capture the effect of exercise.

Comments from Clinical Raters
Oncology - Gynecology

Impact will be muted, as this is a negative trial: exercise is not harmful but doesn't seem to improve any of the outcomes measured, including fatigue.

Why Teal Chicago Ovarian Cancer NBC - Chicago Trump 'teal' tower